Multiple logistic regression analysis of achievement of REM/LDA and functional remission at W54.
| Factors | OR | 95% CI | p |
|---|---|---|---|
| REM (SDAI) at W54, *R2 = 0.3911 | |||
| IFX dosage, mg/kg | 1.127 | 1.017–1.251 | 0.0218 |
| Disease duration, yrs | 0.947 | 0.904–0.987 | 0.0083 |
| SDAI at W14 | 0.843 | 0.800–0.882 | < 0.0001 |
| LDA (SDAI) at W54, *R2 = 0.3087 | |||
| IFX dosage, mg/kg | 1.118 | 1.018–1.232 | 0.0195 |
| SDAI at W14 | 0.906 | 0.880–0.929 | < 0.0001 |
| REM (DAS28-CRP) at W54, *R2 = 0.3847 | |||
| IFX dosage, mg/kg | 1.156 | 1.050–1.277 | 0.0031 |
| DAS28-CRP at W14 | 0.325 | 0.241–0.424 | < 0.0001 |
| LDA (DAS28-CRP) at W54, *R2 = 0.3757 | |||
| IFX dosage, mg/kg | 1.123 | 1.023–1.235 | 0.0143 |
| DAS28-CRP at W14 | 0.347 | 0.264–0.445 | < 0.0001 |
| Functional remission at W54, *R2 = 0.3805 | |||
| IFX dosage, mg/kg | 1.065 | 0.970–1.172 | 0.1872 |
| HAQ at W0 | 0.242 | 0.147–0.386 | < 0.0001 |
| SDAI at W14 | 0.931 | 0.905–0.955 | < 0.0001 |
| Functional remission at W54, *R2 = 0.4059 | |||
| IFX dosage, mg/kg | 1.078 | 0.980–1.188 | 0.1238 |
| Duration of MTX use, yrs | 0.880 | 0.791–0.973 | 0.0125 |
| HAQ at W0 | 0.241 | 0.145–0.387 | < 0.0001 |
| DAS28-CRP at W14 | 0.506 | 0.395–0.637 | < 0.0001 |
Independent variables were selected using a backward stepwise procedure. Functional remission was defined as HAQ ≤ 0.50.
↵* Nagelkerke R2. REM: clinical remission; LDA: low disease activity; HAQ: Health Assessment Questionnaire; W54: Week 54; SDAI: Simplified Disease Activity Index; DAS28-CRP: 28-joint Disease Activity Score-C-reactive protein; B: nonstandardized coefficients; β: standardized coefficients; R2: explained variance; IFX: infliximab; W14: Week 14; W0: Week 0; MTX: methotrexate.